top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

Coya Therapeutics promotes Arun Swaminathan to CEO

Sep 11, 2024
1 min read

Houston, TX, August 19, 2024 (Business Wire) -- Coya Therapeutics has announced the promotion of Arun Swaminathan, Ph.D., to Chief Executive Officer, with the effective date of November 1, 2024. Dr. Swaminathan will also join the Board of Directors, while the company's founder, Dr. Howard Berman, transitions to the role of Executive Chair. This leadership change comes as Coya continues its efforts in developing biologics aimed at enhancing regulatory T cell (Treg) function in the biotech space.

Read full article here.

Recent Posts

UCB to Acquire Candid Therapeutics in Immunology Expansion Deal

Brussels, Belgium, May 3, 2026 (UCB) -- UCB has announced plans to acquire Candid Therapeutics to strengthen its immunology pipeline. The transaction will add novel T-cell engager therapies aimed at

Coloplast Appoints Gavin Wood as New CEO

Humlebaek, Denmark, March 4, 2026 (Coloplast) -- Coloplast has appointed Gavin Wood as its new chief executive officer. The leadership transition is aimed at supporting the company’s long-term strat

ResMed to Acquire Noctrix Health for $340M to Expand into Restless Legs Syndrome

San Diego, CA, April 30, 2026 (Globe Newswire) -- ResMed (NYSE: RMD) signed a definitive agreement to acquire Noctrix Health for $340 million, adding the company's FDA de novo-classified Nidra devic

Comments

Life Science Headlines

UCB to Acquire Candid Therapeutics in Immunology Expansion Deal

Coloplast Appoints Gavin Wood as New CEO

ResMed to Acquire Noctrix Health for $340M to Expand into Restless Legs Syndrome

Teleflex Names Jason Weidman as President and CEO

Sun Pharma to Acquire Organon in $3.1B Deal to Expand Global Women’s Health Portfolio

Beeline Medicines Launches with $300M Series A to Build Precision Autoimmune Pipeline

Modulari-T Biosciences Appoints Tanya E. Borsuk as CEO to Lead Next Phase of Growth

Medtronic Leads $100M Strategic Financing Round in Pulnovo Medical

Paratus Names Alicia Secor as CEO and Expands Leadership Team for Growth

Eli Lilly to Acquire Kelonia Therapeutics in Deal Worth Up to $7B to Boost Cancer Pipeline

bottom of page